Skip to main content
. 2020 Aug 8;15(4):549–565. doi: 10.1007/s11523-020-00736-8

Fig. 1.

Fig. 1

Incidence rates for select AEs experienced by patients with HCC receiving cabozantinib during the CELESTIAL trial [17]. AEs are color coded by system: blue: gastrointestinal; purple: skin and subcutaneous tissue; green: constitutional; orange: hepatic disorders; red: cardiovascular/hematological disorders. AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase, HCC hepatocellular carcinoma, PPE palmar-plantar erythrodysesthesia